The estimated Net Worth of Michael E Lewis is at least $709 Tisíc dollars as of 26 January 2016. Dr Lewis owns over 7,262 units of Cara Therapeutics Inc stock worth over $91,347 and over the last 11 years he sold CARA stock worth over $617,270.
Dr has made over 8 trades of the Cara Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 7,262 units of CARA stock worth $79,374 on 26 January 2016.
The largest trade he's ever made was selling 7,262 units of Cara Therapeutics Inc stock on 26 January 2016 worth over $79,374. On average, Dr trades about 4,841 units every 30 days since 2014. As of 26 January 2016 he still owns at least 314,988 units of Cara Therapeutics Inc stock.
You can see the complete history of Dr Lewis stock trades at the bottom of the page.
Dr. Michael E. Lewis Ph.D. is the Co-Founder & Chief Scientific Advisor at Cara Therapeutics Inc.
Dr D is 69, he's been the Co-Founder & Chief Scientific Advisor of Cara Therapeutics Inc since . There are 1 older and 16 younger executives at Cara Therapeutics Inc. The oldest executive at Cara Therapeutics Inc is Harrison Bains, 76, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON, CT, 06434.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum a Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: